So Covid-19 leader BioNTech has a cancer vaccine in development? Yes, and Regeneron just jumped in for the PhII combo study
Before the coronavirus global emergency stole the R&D show in biopharma, the leaders in the race to develop new mRNA therapies had a big interest in determining if their tech could be used to create an effective cancer vaccine after all the first-gen tries had failed to impress. So perhaps it’s not surprising that an early cut of the data at frontrunner BioNTech went largely unnoticed.
Unless you were at Regeneron.
Premium subscription required
Unlock this article along with other benefits by subscribing to one of our paid plans.